In the second quarter of fiscal 2026, Elite Pharmaceuticals posted revenues of $36.3 million, up 92.4% year over year from $18.9 million, driven largely by the launch and rapid expansion of its ...
Total Revenue: $18.8 million for the quarter, a 109% increase from $8.9 million in the prior year quarter. Operating Income: $3.9 million, up from $1.6 million in the previous year, marking a 141% ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Zacks.com on MSN
ELTP Stock Falls Following Q3 Earnings Decline, Revenue Down Y/Y
Shares of Elite Pharmaceuticals, Inc. ELTP have lost 3.3% since the company reported its earnings for the quarter ended Dec.
Two biotech companies had a rough end to the week last week, and it looks as though things aren’t going to get much better for them heading into the US open on Monday. Here’s what happened. Of the two ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Elite Pharmaceuticals Inc. Annual cash flow by MarketWatch. View ELTP net cash flow, operating cash flow, operating expenses and cash dividends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results